The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study
Objectives: The usefulness of serial procalcitonin (PCT) measurements for predicting the prognosis and treatment efficacy for hospitalised community-acquired pneumonia (CAP) patients was investigated. Methods: This prospective, multicentre, cohort study enrolled consecutive CAP patients who were hos...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-03-01
|
Series: | International Journal of Infectious Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971220300205 |
id |
doaj-109c1aa0f9ca4f39ae310faf6ed944e2 |
---|---|
record_format |
Article |
spelling |
doaj-109c1aa0f9ca4f39ae310faf6ed944e22020-11-25T01:01:15ZengElsevierInternational Journal of Infectious Diseases1201-97122020-03-0192228233The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective studyAkihiro Ito0Isao Ito1Daiki Inoue2Satoshi Marumo3Tetsuya Ueda4Hiroaki Nakagawa5Masato Taki6Atsushi Nakagawa7Shuji Tatsumi8Takashi Nishimura9Tetsuhiro Shiota10Tadashi Ishida11Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, Japan; Corresponding author at: Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, Japan.Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoinkawara-cho, Sakyo-ku, Kyoto, Kyoto 606-8507, JapanDepartment of Respiratory Medicine, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, 2-4-20 Ougimachi, Kita-ku, Osaka, Osaka 530-8480, JapanDepartment of Respiratory Medicine, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, 2-4-20 Ougimachi, Kita-ku, Osaka, Osaka 530-8480, JapanDepartment of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, 2-10-39 Shibata, Kita-ku, Osaka, Osaka 530-0012, JapanDepartment of Respiratory Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, JapanDepartment of Respiratory Medicine, Osaka Red Cross Hospital, 5-30 Fudegasaki, Tennoji-ku, Osaka, Osaka 543-8555, JapanDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojimaminamimachi, Chuo-ku, Kobe, Hyogo 650-0047, JapanDepartment of Airway Medicine, Mitsubishi Kyoto Hospital, 1 Katsuragosho-cho, Saikyo-ku, Kyoto, Kyoto 615-8087, JapanDepartment of Respiratory Medicine, Kyoto Katsura Hospital, 17 Yamadahirao-cho, Saikyo-ku, Kyoto, Kyoto 615-8256, JapanDepartment of Internal Medicine, Yoka Hospital, 1878-1 Yoka, Yoka-cho, Yabu, Hyogo 667-8555, Japan; Department of Respiratory Medicine, Shiga General Hospital, 5-4-30 Moriyama, Moriyama, Shiga 524-8524, JapanDepartment of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, JapanObjectives: The usefulness of serial procalcitonin (PCT) measurements for predicting the prognosis and treatment efficacy for hospitalised community-acquired pneumonia (CAP) patients was investigated. Methods: This prospective, multicentre, cohort study enrolled consecutive CAP patients who were hospitalised at 10 hospitals in western Japan from September 2013 to September 2016. PCT and C-reactive protein (CRP) were measured on admission (PCT D1 and CRP D1), within 48–72 h after admission (PCT D3 and CRP D3), and within 144–192 h after admission. CURB-65 and the Pneumonia Severity Index (PSI) were assessed on admission. The primary outcome was 30-day mortality; secondary outcomes were early and late treatment failure rates. Results: A total of 710 patients were included. The 30-day mortality rate was 3.1%. On multivariate analysis, only PCT D3/D1 ratio >1 [odds ratio (95% confidence interval): 4.33 (1.46–12.82),P = 0.008] and PSI [odds ratio (95% confidence interval): 2.32 (1.07–5.03), P = 0.03] were significant prognostic factors. Regarding treatment efficacy, PCT D3/D1 >1 was a significant predictor of early treatment failure on multivariate analysis. PCT D3/D1 with the PSI significantly improved the prognostic accuracy over that of the PSI alone. Conclusions: PCT should be measured consecutively, not only on admission, to predict the prognosis and treatment efficacy in CAP. Keywords: Biomarker, C-reactive protein, Pneumonia, Procalcitonin, Prognosishttp://www.sciencedirect.com/science/article/pii/S1201971220300205 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Akihiro Ito Isao Ito Daiki Inoue Satoshi Marumo Tetsuya Ueda Hiroaki Nakagawa Masato Taki Atsushi Nakagawa Shuji Tatsumi Takashi Nishimura Tetsuhiro Shiota Tadashi Ishida |
spellingShingle |
Akihiro Ito Isao Ito Daiki Inoue Satoshi Marumo Tetsuya Ueda Hiroaki Nakagawa Masato Taki Atsushi Nakagawa Shuji Tatsumi Takashi Nishimura Tetsuhiro Shiota Tadashi Ishida The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study International Journal of Infectious Diseases |
author_facet |
Akihiro Ito Isao Ito Daiki Inoue Satoshi Marumo Tetsuya Ueda Hiroaki Nakagawa Masato Taki Atsushi Nakagawa Shuji Tatsumi Takashi Nishimura Tetsuhiro Shiota Tadashi Ishida |
author_sort |
Akihiro Ito |
title |
The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study |
title_short |
The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study |
title_full |
The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study |
title_fullStr |
The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study |
title_full_unstemmed |
The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study |
title_sort |
utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: a multicentre, prospective study |
publisher |
Elsevier |
series |
International Journal of Infectious Diseases |
issn |
1201-9712 |
publishDate |
2020-03-01 |
description |
Objectives: The usefulness of serial procalcitonin (PCT) measurements for predicting the prognosis and treatment efficacy for hospitalised community-acquired pneumonia (CAP) patients was investigated. Methods: This prospective, multicentre, cohort study enrolled consecutive CAP patients who were hospitalised at 10 hospitals in western Japan from September 2013 to September 2016. PCT and C-reactive protein (CRP) were measured on admission (PCT D1 and CRP D1), within 48–72 h after admission (PCT D3 and CRP D3), and within 144–192 h after admission. CURB-65 and the Pneumonia Severity Index (PSI) were assessed on admission. The primary outcome was 30-day mortality; secondary outcomes were early and late treatment failure rates. Results: A total of 710 patients were included. The 30-day mortality rate was 3.1%. On multivariate analysis, only PCT D3/D1 ratio >1 [odds ratio (95% confidence interval): 4.33 (1.46–12.82),P = 0.008] and PSI [odds ratio (95% confidence interval): 2.32 (1.07–5.03), P = 0.03] were significant prognostic factors. Regarding treatment efficacy, PCT D3/D1 >1 was a significant predictor of early treatment failure on multivariate analysis. PCT D3/D1 with the PSI significantly improved the prognostic accuracy over that of the PSI alone. Conclusions: PCT should be measured consecutively, not only on admission, to predict the prognosis and treatment efficacy in CAP. Keywords: Biomarker, C-reactive protein, Pneumonia, Procalcitonin, Prognosis |
url |
http://www.sciencedirect.com/science/article/pii/S1201971220300205 |
work_keys_str_mv |
AT akihiroito theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT isaoito theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT daikiinoue theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT satoshimarumo theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT tetsuyaueda theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT hiroakinakagawa theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT masatotaki theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT atsushinakagawa theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT shujitatsumi theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT takashinishimura theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT tetsuhiroshiota theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT tadashiishida theutilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT akihiroito utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT isaoito utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT daikiinoue utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT satoshimarumo utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT tetsuyaueda utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT hiroakinakagawa utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT masatotaki utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT atsushinakagawa utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT shujitatsumi utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT takashinishimura utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT tetsuhiroshiota utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy AT tadashiishida utilityofserialprocalcitoninmeasurementsinadditiontopneumoniaseverityscoresinhospitalisedcommunityacquiredpneumoniaamulticentreprospectivestudy |
_version_ |
1725209870606532608 |